# BioXell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioxell

- Industry: Biotechnology
- Headquarters: Italy
- Website: www.bioxell.com
- Total disclosed funding: $80M
- Latest round: Series C (Mar 15, 2006)
- Investors on record: 10

## About

BioXell is a clinical stage biopharmaceutical company, researches, discovers, and develops drug candidates for unmet medical needs in urology, inflammation, pain, and other related disorders.

## Funding rounds

- Series C, Mar 15, 2006, $13M — Index Ventures, TVM Capital Life Science, EQT Life Sciences, BB Biotech
- Series C, Oct 20, 2004, $29M — Index Ventures, MVM Partners, AlpInvest Partners, Daiwa Corporate Investment, BB Biotech, MPM BioImpact, QVentures
- Series B, May 21, 2003, $20M — Index Ventures, AlpInvest Partners, EQT Life Sciences, MPM BioImpact
- Series A, Mar 27, 2002, $19M — Index Ventures, EQT Life Sciences, Roche USA Pension Plan, MPM BioImpact

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series A, Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B, Series C
- Roche USA Pension Plan — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- AlpInvest Partners — Series B, Series C
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series C
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series C
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series C
- QVentures (https://capitalatlas.ai/funds/qventures) — Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C